Dowell JA - Search Results

1

Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide.

Buckwalter M, Dowell JA. Buckwalter M, et al. Among authors: dowell ja. J Clin Pharmacol. 2005 Nov;45(11):1279-87. doi: 10.1177/0091270005280378. J Clin Pharmacol. 2005. PMID: 16239361 Clinical Trial.

2

Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.

Buckwalter M, Dowell JA, Korth-Bradley J, Gorovits B, Mayer PR. Buckwalter M, et al. Among authors: dowell ja. J Clin Pharmacol. 2004 Aug;44(8):873-80. doi: 10.1177/0091270004267595. J Clin Pharmacol. 2004. PMID: 15286091 Clinical Trial.

3

Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.

Dowell JA, Goldstein BP, Buckwalter M, Stogniew M, Damle B. Dowell JA, et al. J Clin Pharmacol. 2008 Sep;48(9):1063-8. doi: 10.1177/0091270008321273. Epub 2008 Jul 16. J Clin Pharmacol. 2008. PMID: 18633123

4

Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.

Marbury T, Dowell JA, Seltzer E, Buckwalter M. Marbury T, et al. Among authors: dowell ja. J Clin Pharmacol. 2009 Apr;49(4):465-76. doi: 10.1177/0091270008330162. J Clin Pharmacol. 2009. PMID: 19318696 Clinical Trial.

5

Pharmacokinetics of dalbavancin in plasma and skin blister fluid.

Nicolau DP, Sun HK, Seltzer E, Buckwalter M, Dowell JA. Nicolau DP, et al. Among authors: dowell ja. J Antimicrob Chemother. 2007 Sep;60(3):681-4. doi: 10.1093/jac/dkm263. Epub 2007 Jul 12. J Antimicrob Chemother. 2007. PMID: 17631507 Clinical Trial.

6

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.

Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Dowell JA, et al. J Clin Pharmacol. 2004 Jun;44(6):590-8. doi: 10.1177/0091270004265644. J Clin Pharmacol. 2004. PMID: 15145966 Clinical Trial.

7

Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.

Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, White RJ, Henkel TJ. Dorr MB, et al. J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii25-30. doi: 10.1093/jac/dki008. J Antimicrob Chemother. 2005. PMID: 15750034 Review.

8

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T; Dalbavancin Skin and Soft-Tissue Infection Study Group. Seltzer E, et al. Among authors: dowell ja. Clin Infect Dis. 2003 Nov 15;37(10):1298-303. doi: 10.1086/379015. Epub 2003 Oct 17. Clin Infect Dis. 2003. PMID: 14583862 Clinical Trial.

9

Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease.

Knebel W, Palmen M, Dowell JA, Gastonguay M. Knebel W, et al. Among authors: dowell ja. J Clin Pharmacol. 2008 Jul;48(7):837-48. doi: 10.1177/0091270008318218. Epub 2008 May 19. J Clin Pharmacol. 2008. PMID: 18490498 Clinical Trial.

10

Pharmacokinetics and excretion of dalbavancin in the rat.

Cavaleri M, Riva S, Valagussa A, Guanci M, Colombo L, Dowell J, Stogniew M. Cavaleri M, et al. J Antimicrob Chemother. 2005 Mar;55 Suppl 2:ii31-5. doi: 10.1093/jac/dki006. J Antimicrob Chemother. 2005. PMID: 15750035

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page